BriaCell Therapeutics Corporation

BCTXW
0,5906
0,0406 (7,38%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 22:44:07
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Warrant Azionario
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
17/5/202422:51EDGAR2Form 8-K - Current report
17/5/202422:33GLOBEBriaCell Therapeutics Announces Closing of $5.0 Million..
16/5/202423:10EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/5/202414:00GLOBEBriaCell Therapeutics Announces Pricing of $5.0 Million..
24/4/202414:00GLOBEBriaCell Announces Oral and Poster Presentations at ASCO..
10/4/202414:00GLOBEBriaCell 2024 AACR Preclinical Poster Confirms Strong..
09/4/202414:00GLOBEBriaCell Showcases Data Demonstrating Unmatched..
07/3/202414:00GLOBEBriaCell Receives and Executes Letter of Intent to Advance..
06/3/202414:00GLOBEBriaCell to Present Clinical Data in Central Nervous System..
27/2/202414:00GLOBEBriaCell Provides Update on Alleged Illegal Trading of..
07/2/202414:00GLOBEBriaCell Announces Strong Clinical Data in Breast Cancer..
06/2/202414:30GLOBEBreaking Ground in Prostate Cancer: BriaCell Announces Lead..
31/1/202404:48GLOBEBriaCell Therapeutics Corp. Announces Results of Shareholder..
04/1/202414:45GLOBEBriaCell Images Confirm Robust Anti-Tumor Activity in..
28/12/202314:55GLOBEBriaCell Reports 71% Central Nervous System Response Rate in..
20/12/202314:40GLOBEBriaCell Reports Unprecedented Preliminary Survival and..
06/12/202315:31GLOBEBriaCell Highlights Outstanding Topline Survival and..
06/12/202315:00GLOBEBriaCell 2023 SABCS Posters Confirm Activation of..
30/11/202313:00GLOBEBriaCell Records New Responder with Remarkable Improvement..
03/11/202313:31GLOBEBriaCell Reports Unprecedented Anti-Tumor Activity of its..
25/10/202315:15GLOBEBriaCell Forms Medical Advisory Board of Distinguished..
20/10/202315:15GLOBEOctober is Breast Cancer Awareness Month – BriaCell is..
18/10/202315:00GLOBEBriaCell Announces Presentations at the 2023 Society for the..
11/10/202315:10GLOBEBriaCell To Host Virtual Key Opinion Leader Event on..
04/10/202315:00GLOBEBriaCell Partners with New York Cancer & Blood Specialists..
03/10/202315:00GLOBEBriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in..
08/9/202313:00GLOBEBriaCell Reports Benchmark-Beating Patient Survival and..
31/8/202317:54GLOBEBriaCell Therapeutics Corp. Announces Closing of Plan of..
31/8/202314:21GLOBEBriaCell Accepts Letter of Intent from Weill Cornell..
25/8/202320:33GLOBEBriaCell Receives Court Approval for the Share Arrangement..
18/8/202318:21GLOBEBriaCell Therapeutics Corp. Announces Voting Results From..
16/8/202314:36GLOBEBriaCell Awarded National Cancer Institute Grant to Advance..
27/6/202314:05GLOBEFDA Approves BriaCell’s Pivotal Registrational Study Design..
25/5/202315:00GLOBEBriaCell Enters Definitive Arrangement Agreement for the..
19/5/202317:38GLOBEBriaCell Closes $4 Million Strategic Investment by Prevail..
Apertura: 0,62 Min: 0,5101 Max: 0,62
Chiusura: 0,55

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network